Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall purpose with this investigation was to increase access to cognitive behavioural therapy for insomnia (CBT-I) by examining CBT-I delivered through a smartphone application
The first aim that will be addressed is to explore the efficacy of the smartphone delivered CBT-I on overall insomnia and on nighttime symptoms by comparing CBT-I to a waitlist control in a randomised controlled trial.
The second aim is to investigate the effect smartphone delivered CBT-I compared to the waitlist on secondary outcomes related to insomnia, such as stress, anxiety, depression, quality of life and functional impairment.
The third aim that will be addressed is to examine what patient characteristics that CBT delivered to a smartphone depend on to be effective with a treatment-moderator strategy. To investigate moderators, the following moderators will be assessed; age, gender, occupational status, level of education, initial insomnia severity, dysfunction, medication use, chronic pain, somatic/psychiatric co-morbidity, and proposed behavioral mediators of sleep restriction and stimulus control will also be employed as moderators.
The fourth aim that will be addressed is to examine behavioural processes of sleep restriction and stimulus control as potential mediators of treatment outcome.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cognitive Behavioural Therapy | Experimental | Cognitive Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles and to a lesser extent some cognitive exercises. focused on handling sleep disturbing thought activities. |
|
| Waitlist | No Intervention | The waitlist serves as a passive control which will receive the same measures as the cognitive behaviour therapy group. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cognitive Behavioural Therapy | Behavioral | Sleep restriction, Stimulus control, sleep hygiene and cognitive techniques to handle sleep disturbing thoughts. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Insomnia severity index | Global measure of insomnia severity, used for assessing change in insomnia severity from pretreatment to posttreatment. | Pretreatment (week 0), during treatment (i.e., weekly: 1, 2, 3, 4, 5), post-treatment (week 6) and follow-up at 3 month after treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Work and Social Adjustment Scale | Score: 0-40, with higher scores indicating worse outcome. | Pretreatment (week 0), post-treatment (week 6) and follow-up at 3 month after treatment |
| Sleep onset latency (SOL) |
| Measure | Description | Time Frame |
|---|---|---|
| Credibility Expectancy Questionnaire. | Score: 4 items, 1-9, 2 items 0-10, with higher scores indicating higher credibility and expectancy. | During the first treatment module (first week of treatment). |
| Client Satisfaction Questionnaire. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rikard Sunnhed, PhD | Karolinska Institutet | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Karolinska institute | Stockholm | Stockholm County | Sweden |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007319 | Sleep Initiation and Maintenance Disorders |
| D017008 | Negotiating |
| ID | Term |
|---|---|
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015928 | Cognitive Behavioral Therapy |
| ID | Term |
|---|---|
| D001521 | Behavior Therapy |
| D011613 | Psychotherapy |
| D004191 | Behavioral Disciplines and Activities |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Pretreatment (week 0), during treatment (i.e., weekly: 1, 2, 3, 4, 5), post-treatment (week 6). |
| Wake time after sleep onset (WASO). | Pretreatment (week 0), post-treatment (week 6). |
| Early morning awakenings (EMA). | Pretreatment (week 0), post-treatment (week 6). |
| Total sleep time (TST). | Pretreatment (week 0), post-treatment (week 6). |
| Depression, anxiety and stress scale-21 | Score: 0-63, with higher scores indicating worse outcome. | Pretreatment (week 0), post-treatment (week 6) and follow-up at 3 month after treatment. |
| Brunnsviken Brief Quality of life index | Score: 0-96, with higher scores indicating better quality of life. | Pretreatment (week 0), post-treatment (week 6) and follow-up at 3 month after treatment. |
| Bed and rise time variability | Pretreatment (week 0), during treatment (i.e., weekly: 1, 2, 3, 4, 5), post-treatment (week 6). |
| Time in bed (TIB) | Pretreatment (week 0), during treatment (i.e., weekly: 1, 2, 3, 4, 5), post-treatment (week 6). |
| Pre sleep arousal scale | Score: 16-80, with higher scores indicating worse outcome. | Pretreatment (week 0), during treatment (i.e., weekly: 1, 2, 3, 4, 5), post-treatment (week 6) and follow-up at 3 month after treatment. |
Score: 8-32, with higher scores indicating higher satisfaction.
| Post-treatment (week 6) |
| Activity and adherence with treatment protocol (self developed questionnaire assessing treatment activity and adherence relating to text, homework and therapist support). | Score ranging from 1-5, with higher scores indicating higher activity and adherence. | Post-treatment (week 6) |
| three items assessing sick-leave and other concomitant treatment (self developed questionns). | Item one assessing number of days on sick-leave. Item two assessing whether participants have sought other healthcare options. Item three assessing whether participants have received other treatments for their sleeping issues during the specified time frames. | Post-treatment (week 6) and at 3-month follow-up. |
| Adverse events (questionnaire from a previous similar study). | Post-treatment (week 6) |
| Changes in suicide risk (Item 9 from the MADRS). | Score: 0-6, with higher scores indicating a higher suicide risk. | Pretreatment (week 0), post-treatment (week 10) and follow-up at 6 month after treatment. |
| D001523 |
| Mental Disorders |
| D003142 | Communication |
| D001519 | Behavior |